Watch and listen to CML topics featuring experts, patients, and more

Conversations in Care: Establishing Good Rapport

5 min watch

Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, discuss how to manage a patient with CML on their second TKI who may not be communicating their tolerability issues with their health care team.

Conversations in Care: Considering Switching Treatments

4 min 17 sec watch

Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, review possible next steps when a patient with CML on an effective second TKI wants to switch therapies due to a side effect that may be manageable.

Conversations in Care: Diving Deeper

4 min 56 sec watch

Dr Ted Braun and Diana Brewer, PA-C, of the Oregon Health & Science University Knight Cancer Center, consider solutions for a patient with CML who may be undermining their TKI therapy by treating a comorbidity with an over-the-counter drug that reduces TKI efficacy.

How Do You Monitor TKI Tolerability Issues Among Patients Receiving TKIs?

1 min 5 sec watch

Moshe Talpaz, MD, describes the importance of a strong team and early action for monitoring TKI tolerability issues among his patients receiving TKIs.

How Does Intolerance Impact Clinical Decisions?

39 sec watch

Javier Pinilla-Ibarz, MD, PhD, discusses how intolerance to TKIs impact clinical decisions in later lines of therapy for CML-CP compared to earlier lines of therapy.

Missing the Mark in CML

7 min 15 sec watch

Moshe Talpaz, MD, and Eri Matsuki, MD, discuss tolerability issues in later lines of CML and when a treatment switch may be necessary.

Overcoming Resistance

8 min 3 sec watch

Jorge Cortes, MD, and Carla Boquimpani, MD, analyze the consequences of treatment resistance in later lines of CML.

Choosing What to Change in CML

7 min 12 sec watch

Valentin Garcia Gutierrez, MD, PhD, and Gabriela Hobbs, MD, review case studies and discuss different management strategies for patients experiencing TKI intolerance.

FAQ: What Is the Most Common HCP Question About CML?

58 sec watch

Jorge Cortes, MD, discusses the most common question HCPs ask him: "When a patient with CML is resistant to treatment, what do I do next?"

FAQ: Is Switching Due to Low-Grade AEs Appropriate?

1 min 7 sec watch

Moshe Talpaz, MD, talks about the importance of considering low-grade AEs when it comes to treating patients in later lines of CML.

FAQ: Dose Adjustment or Switch?

1 min 18 sec watch

Jorge Cortes, MD, discusses how to approach different clinical scenarios for patients in later lines of therapy for CML.